Physician profile
Ivan Arenas
NPI 1821227760
$2,496.34
in general payments reported to CMS, 2019-2025
13 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $147 · 2021: $159 · 2022: $33.10 · 2023: $1,345 · 2024: $180 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $997 · Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $997.05 |
| Food and Beverage | $643.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,377.18 | 2021-2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $245.21 | 2019-2020 | |
| Abbott Laboratories | $175.57 | 2019-2025 | Cardiomems |
| Abiomed | $167.83 | 2024-2025 | Impella |
| Pfizer INC. | $148.65 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $99.24 | 2019-2021 | |
| Amgen INC. | $69.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.56 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $47.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.11 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $25.57 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.64 | 2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $18.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Arenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.